IMTX · Immatics N.V.
Market Cap
$1.14B
Shares
152.23M
Volume · Oct 20
1.49M
Avg daily vol (3M)
711.42K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.51
Open$7.07
Day$6.94–7.61
52W close$6.73–11.87
Avg vol 30d902K
Short int3.7M · 2.4% float · 4.2d
Short vol19%
DataJan 2020–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-23.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.3%
Year over year · more shares
Price change (1Y)
-28.6%
Trailing year
Short interest
2.4%
Latest settlement · 4.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−22%
below
Price vs 50-day avg
−12%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
15%
mid-range
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−33%
trailing
YTD return
−28%
this year
Relative strength
−41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
6 of 83 funds reported for Sep 30 · net +11.0K sh shares · +2 new
Insider flow
Accumulating
Net +$7.5M over 90 days · 0% sells
Short interest
Falling
2.42% of float · ▼ -16.8% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
83 holders — mid 3-yr range
Squeeze score
39
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
58%
annualized · 1-yr
Max drawdown
−43%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−22%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
15%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
6 of 83 funds reported for Sep 30 · net +11.0K sh shares · +2 new
Insider flow
Accumulating
Net +$7.5M over 90 days · 0% sells
Short interest
Falling
2.42% of float · ▼ -16.8% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
83 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $8 · 15%
Range high $12
vs 200-day avg -22%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMTX
this stock
Immatics N.V.
|
$1.14B | -28.5% | — | — | 2.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMTX | +10.0% | -15.3% | -33.0% | -14.5% | -28.5% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +11.1% | -14.8% | -41.0% | -15.3% | -41.3% |